Respiratory DiseaseREHABPSYNCT06229600
REspiratory reHABilitation and PSYchiatric Comorbidities
An observational study of Respiratory Disease, run by Istituti Clinici Scientifici Maugeri SpA at 6 sites in Italy.
Trial summary
Patients with respiratory insufficiency, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, asthma, bronchiectasis, and, to a lesser extent, other pathologies that result in respiratory insufficiency and require rehabilitation are admitted to in-hospital Respiratory Rehabilitation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Respiratory Disease
- What is being tested?
- Standard rehabilitation
- How many people
- 994 participants
- Where
- 6 sitesItaly
- Study dates
- 2 Jan 2024to 31 Jul 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: On admission (T0), clinical history, admission diagnosis, and current medication history will be collected for all patients admitted for respiratory rehabilitation. All patients will follow their tailored rehabilitation program according to the medical indication. At the time of discharge, they will be classified into six groups (A-F) according to the presence/absence of a psychiatric/cognitive diagnosis and/or pharmacological therapy.
Who may be able to join
- Older than 18 years of age, of either sex, eligible for admission to a Respiratory Rehabilitation Unit and who have signed the informed consent attesting to the patient's voluntary participation.
Who cannot join
- Patients unable to read, with significant speech and hearing impairment,or refusing participation.
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
Italy6 sites
Istituti Clinici Scientifici Maugeri
Bari
Istituti Clinici Scientifici Maugeri
Lumezzane, Brescia, 25065
Istituti Clinici Scientifici Maugeri
Milan
Istituti Clinici Scientifici Maugeri
Montescano, Pavia
Istituti Clinici Scientifici Maugeri
Pavia, 27100
Istituti Clinici Scientifici Maugeri
Telese Terme, Benevento
About this study
Official title: Respiratory Rehabilitation and the Impact of Psychiatric Comorbidities
Patients with respiratory insufficiency, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, asthma, bronchiectasis, and, to a lesser extent, other pathologies that result in respiratory insufficiency and require rehabilitation are admitted to in-hospital Respiratory Rehabilitation. Several studies have assessed the impact of comorbidities in the most frequent respiratory diseases such as COPD, asthma, pulmonary fibrosis, and cystic fibrosis in terms of worsening mortality, morbidity, and disease progression.
However, to our knowledge, there is no reliable quantification in Italy of the percentage of the presence of mental disorders (psychiatric/neurodegenerative) according to the Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-5 classification in respiratory patients as well as the prevalence of mental disorders present among patients requiring in-hospital rehabilitation programs.
The study hypothesizes that these disorders are present among patients admitted to rehabilitation centers and that they may impact the final rehabilitation outcome.
Read the detailed description
Patients with respiratory insufficiency, COPD, pulmonary fibrosis, asthma, bronchiectasis, and, to a lesser extent, other pathologies that result in respiratory insufficiency and require rehabilitation are admitted to in-hospital Respiratory Rehabilitation. Several studies have assessed the impact of comorbidities in the most frequent respiratory diseases such as COPD, asthma, pulmonary fibrosis, and cystic fibrosis in terms of worsening mortality, morbidity, and disease progression.
Comorbidities have been studied and assessed by scales such as the COTE, the Charlson comorbidity index (CCI), and the Cumulative Illness Rating Scale (CIRS). These comorbidities assessed predominantly focus on metabolic and cardiovascular aspects and only a small number of studies considered psychiatric comorbidity, mainly depression.
In previous studies depression, anxiety and psychiatric disease were 8th, 14th, and 23rd in frequency as comorbidity.
Other, more evaluated comorbidities were high blood pressure (17%-64.7%), coronary artery disease (19.9%-47.8%), diabetes mellitus (10.2%-45%) osteoarthritis (18%-43.8%), psychiatric conditions (12.1%-33%) and asthma (14.7%-32.5%).
Among psychological/psychiatric/neurodegenerative comorbidities, anxiety, and depression have been more extensively studied, with worse rehabilitation outcomes, more symptoms (especially dyspnoea), less functional exercise capacity, and minor quality of life (QOL). Similarly, patients with COPD and obstructive sleep apnea syndrome (OSAS), as demonstrated in numerous studies, are more frequently affected by neurocognitive disorders.
Gender differences in reporting psychiatric and respiratory comorbidity have been previously observed: twice as many psychiatric disorders in women as in men, and with higher levels of anxiety and depression in women than in men.
Pulmonary diseases are historically and etiologically related to smoking and unfavorable environmental exposures, two factors that are more present in less affluent social groups, where an increase in psychiatric diseases is known. People with psychiatric diseases and fewer contextual resources also arrive later to be diagnosed with COPD and/or lung cancer, thus leading to a more unfavorable course.
Respiratory rehabilitation is for some respiratory diseases the standard of care among non-pharmacological therapies and should possibly lead to a return to a state of health identified as the person's 'well-being'. As recently published in a study conducted by the Italian Health Ministry, only 18% of Italians feel in a state of full well-being, understood as a state of complete physical, mental, and social well-being and not simply the absence of disease', indicating how complex it is to achieve this state, particularly for people with respiratory pathologies.
In recent years, therefore, there has been growing scientific evidence that there is a close correlation between mental and physical health to achieve maximum well-being also understood as 'the ability to adapt and self-manage in the face of social, physical and emotional challenges. For some years now, and even more after the recent severe acute respiratory syndrome (SARS)-CoV-2 pandemic outbreak, more and more attention has been paid to psychological and psychiatric disorders, especially anxiety, depression, and substance abuse.
Patients admitted to in-hospital respiratory rehabilitation often have complex comorbidities that affect recovery after an acute event.
These studies suggest that psychiatric/neurodegenerative pathologies may therefore significantly impact the patient's condition by increasing the risk of developing pulmonary disease, slowing down diagnosis and treatment, and acting as a brake on the possibility of deriving maximum benefit from pharmacological and non-pharmacological treatments such as rehabilitation and the continuation of adequate chronic disease management at home.
To our knowledge, there is no reliable quantification in Italy of the percentage of the presence of mental disorders (psychiatric/neurodegenerative) according to the DSM-5 classification in respiratory patients as well as the prevalence of mental disorders present among patients requiring in-hospital rehabilitation treatment.
The study hypothesizes that these disorders are present among patients admitted to rehabilitation centers and that they may impact the final rehabilitation outcome for various reasons, including a reduced awareness of one's health condition, greater difficulty in therapeutic adherence, the ability to self-monitor, the reduction of risk factors and a reduced availability of resources. This also results in reduced effectiveness of the education provided.
The presence of mental disorders also has a significant impact on family members and caregivers who should ultimately participate in the full implementation of the rehabilitation project. We consider as important to evaluate this aspect as well with this Italian-based survey.
With this study we therefore intend to assess in our Institutes how many people arrive with a diagnosis and/or treatment for mental disorders, how many need attention, and how many are identified or suspected to be affected by a psychiatric/neurodegenerative disease during their stay, during routine assessments, collecting clinical history, treatment and comorbidities. Treating the patient as a clinical team with multiple approaches, it can be argued that clinically significant signs and symptoms of psychiatric/neurocognitive disorders are detected with adequate accuracy even in the absence of formal psychiatric assessment, which would make the study unduly burdensome in the setting of interest and could undermine patient acceptance.
All adult patients consecutively admitted for a course of Respiratory Rehabilitation - in 12 months - to the Units of Respiratory Rehabilitation belonging to the Department of Pneumology of the Maugeri Scientific Clinical Institutes will be studied. On admission (T0), anthropometric, clinical history (comorbidities measured with CIRS scale, presence of chronic respiratory failure (CRF), oxygen (O2) use, smoking history with number of packs/year, drug therapy, number of respiratory flare-ups per year, number of respiratory hospitalizations per year, days since respiratory index event, admission diagnosis, and current medication history will be collected.
Moreover:
- Frailty assessment: Sunfrail tool (ST) is a questionnaire for measuring frailty among older people. ST is a 9-item questionnaire consisting of nine questions selected from evidence-based tools already used in health services in the European Union and the USA to identify frailty in the bio (physical), psycho (cognitive and psychological), and social domains. The answer can be yes or no. Important is the percentage of yes, and important is frailty.
- Pulmonary function assessment of forced expiratory volume at one second (FEV1), forced vital capacity (FVC), and FEV1/FVC; if the patient is respiratory insufficient: saturation of oxygen (SatO2) in oxygen/air, oxygen desaturation index (ODI)/h, average night SatO2, and time under 90% oxygen saturation (T<90).
- Psychological/neuropsychological assessment by the Centre's psychologists only if specifically requested during the rehabilitation program by the relevant clinician.
- Sleep survey: Insomnia Severity Index. Designed as a brief screening tool for insomnia, the seven-item questionnaire Insomnia Severity Index (ISI) asks respondents to rate the nature and symptoms of their sleep problems using a Likert-type to rate each item (e.g., 0 = no problem; 4 = very severe problem), yielding a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).
At the time of discharge from rehabilitation, patients will be classified according to the group A-F definition.
- Conditions
- Respiratory Disease
- Being tested
- Standard rehabilitation
- Keywords
- Chronic respiratory insufficiency, Cognitive impairment, Mental Health, COPD, Lung diseases
- Medical subject headings
- Respiration Disorders, Cognitive Dysfunction, Psychological Well-Being, Pulmonary Disease, Chronic Obstructive, Lung Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard rehabilitationOther
Respiratory rehabilitation
| Study group | Role | What they receive |
|---|---|---|
| Group A | Patients with an established diagnosis according to the DSM-5 classification (DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS - FIFTH EDITION, 2014) and possible drug therapy (24).
* Schizophrenia spectrum disorders and other psychotic disorders
* Bipolar disorder and related disorders
* Depressive disorders
* Anxiety disorders
* Obsessive-compulsive disorder and related disorders
* Disorders related to traumatic and stressful events
* Dissociative disorders
* Somatic symptoms and related disorders
* Nutrition and eating disorders
* Evacuation disorders
* Sleep-wake disorders
* Sexual dysfunctions
* Gender dysphoria
* Disruptive behaviour, impulse control and conduct disorder
* Substance-related and addiction disorders
* Personality disorders
* Paraphilia disorders
* Autism spectrum disorders
* ADHD Receives: Other: Standard rehabilitation | |
| Group B | Patients on medication (psychotropic drugs) without a reported/reported specific psychiatric diagnosis in their clinical history. Receives: Other: Standard rehabilitation | |
| Group C | Patients without a history/reported psychiatric disorder and without specific psychopharmacological therapy. Receives: Other: Standard rehabilitation | |
| Group D | Patients with a history of diagnosed neurocognitive disorder. Receives: Other: Standard rehabilitation | |
| Group E | Patients in the practice without a history/report of psychiatric disorders and without specific psychopharmacological treatment on admission who are diagnosed during admission.
This is a subgroup of the C group. Receives: Other: Standard rehabilitation | |
| Group F | Patients in the practice without a history/report of psychiatric disorders and without specific psychopharmacological therapy on admission who are diagnosed during admission for suspected psychiatric/neurocognitive pathology and are discharged with indications for further investigation at the territorial services.
This is a subgroup of the C group. Receives: Other: Standard rehabilitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Frequency of patients with or without comorbidities of psychiatric/neurocognitive disorders present on discharge from a respiratory rehabilitation program
To quantify the percentage of patients in the study with or without comorbidities of psychiatric/neurocognitive disorders present on discharge from a respiratory rehabilitation pathway as follows:
- established psychiatric diagnosis and drug therapy
- drug therapy (psychotropic drugs) without a specific psychiatric diagnosis reported/reported in the history
- no history/reported psychiatric disorder and no specific psychopharmacological therapy
- history of diagnosis of neurocognitive disorder
- absence of history/report of psychiatric disorders and without specific psychopharmacological treatment in inpatients receiving a diagnosis during admission
- absence of history/report of psychiatric disorders and without specific psychopharmacological therapy on admission who receive a diagnosis during admission for suspected psychiatric/neurocognitive pathology and are discharged with indications for further investigation at the territorial services
Measured: At one month
Secondary outcomes (8)
Gender difference
To assess whether there are differences in the presence of mental disorders between males and females and whether there are pathological pictures with different prevalence between men and women
Measured: At one month
Response to rehabilitation on disease impact: CAT
To assess whether the different groups of patients present a different pattern of response to rehabilitation in terms of rehabilitation outcome, several tests will be performed both at admission and discharge:
For disease impact, CAT will be used. CAT is a questionnaire that can help you and a doctor discuss the impact COPD has on your daily life.
CAT asks questions about eight areas, prompting you to assign a score ranging from 0 to 5 for each area.
A score of 0 means there's no impairment in that area. A score of 5 means severe impairment. Your overall score will range from 0 to 40. Higher scores indicate your COPD has a greater impact on your overall health and well-being.
Measured: At baseline and one month
Response to rehabilitation on motor disability: Barthel Index
For motor disability, Barthel Index will be used both at admission and discharge. Barthel Index for Activities of Daily Living is an ordinal scale that measures a person's ability to complete activities of daily living (ADL).
The Barthel Index measures the degree of assistance required by an individual on ten mobility and self-care ADL items. The ten items are scored with several points, and then a final score (maximum 100) is calculated by summing the points awarded to each functional skill. This allows the examiner to measure a patient's functional disability by quantifying their performance. The higher the score (100), the more independent the patient is in completing the measured ADLs. Higher scores also indicate the patient is more likely to return home, with varying degrees of assistance, following hospital discharge. The lower the score (0), the more dependent the patient is on ADL completion, and the more skilled care will be required at discharge.
Measured: At baseline and one month
Response to rehabilitation on frailty: BRASS
For frailty assessment, BRASS will be used both at admission and discharge. BRASS was developed as part of a system of planning for total (non-relapsing) discharge, above all for patients over the age of 65. It facilitates the identification of those at risk of prolonged hospitalization and/or a complicated discharge procedure.
According to the BRASS score, three risk classes will be identified by the nurse:
- low risk (score from 0 to 10): subjects that do not require special efforts for the organization of their resignation, disability is very limited;
- medium risk (score 11 to 19): patients with problems related to complex clinical situations that require discharge planning, but probably no risk of institutionalization;
- high risk (score greater than or equal to 20): subjects who reported problems and require a continuity of care, probably, in rehabilitation facilities or institutions.
Measured: At baseline and one month
Response to rehabilitation on dyspnea symptoms: Medical Research Council (MRC)
For dyspnea symptoms, MRC will be used both at admission and discharge. This scale measures perceived respiratory disability, using the World Health Organization (WHO) definition of disability being "any restriction or lack of ability to perform an activity in the manner or within the range considered normal for a human being". The mMRC (Modified Medical Research Council) Dyspnoea Scale is used to assess the degree of baseline functional disability due to dyspnoea. It is useful in characterizing baseline dyspnoea in patients with respiratory diseases such as COPD. The mMRC breathlessness scale ranges from grade 0 to 4, where 4 is the worse score.
Measured: At baseline and one month
Response to rehabilitation on dyspnea symptoms: Barthel Dyspnoea Index (Bld)
For dyspnea symptoms related to activities of daily living, Barthel Dyspnoea Index (Bld) will be used both at admission and discharge. BId is a recent dyspnea scale integrating ten daily life activities of the Barthel index and five categories of dyspnea sensation intensity. BId scale was reported to be reliable, sensitive, and adequate as a tool for measuring the level of dyspnea while performing daily life activities and the responsiveness after treatment. The total BId score ranges from 0 (no dyspnea) to 100 (maximum level of dyspnea). A decrease in BId score represents an improvement, whereas an increase in the score represents a worsening in symptoms.
Measured: At baseline and one month
Response to rehabilitation on effort tolerance: 6-Minute Walking Test (6MWT)
For effort tolerance assessment, the 6-minute walking test (6MWT) will be used both at admission and discharge. The object of this test is to walk as far as possible for 6 minutes. The patient will walk back and forth along this course (demonstrate one lap) for six minutes. The patient may slow down if necessary. If the patient stops, I want you to continue to walk again as soon as possible. It evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. It is measured in meters, more meters best performance.
Measured: At baseline and one month
Prevalence of the anamnestic factors in all groups
To assess the prevalence of all anamnestic factors collected at admission in the study groups.
Measured: At baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jan 2024
- Study start2 Jan 2024
- Primary completion31 Mar 2025
- Study completion31 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Respiratory DiseaseStudies of the same condition, open and under way.
- More trials run by Istituti Clinici Scientifici Maugeri SpAThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 994 participants (actual)
Sponsor and investigators
- Lead sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Michele Vitacca, MD, Principal investigator, Istituti Clinici Scientifici Maugeri
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06229600
- Sponsor's protocol ID
- CET 2023-3.11/439.1
- Acronym
- REHABPSY
- Status last verified
- Apr 2025
- First submitted
- 29 Dec 2023
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: All collaborating centers will manage pseudo-anonymized data by a proper eCRF to the coordinating center (ICSM Lumezzane) at the end of each month for 12 months. Data will be collected in a unique database managed by a health professional external to the research.
Publications
De Luca V, Femminella GD, Leonardini L, Patumi L, Palummeri E, Roba I, Aronni W, Toccoli S, Sforzin S, Denisi F, Basso AM, Ruatta M, Obbia P, Rizzo A, Borgioli M, Eccher C, Farina R, Conforti D, Mercurio L, Salvatore E, Gentile M, Bocchino M, Sanduzzi Zamparelli A, Viceconte G, Gentile I, Ruosi C, Ferrara N, Fabbrocini G, Colao A, Triassi M, Iaccarino G, Liotta G, Illario M. Digital Health Service for Identification of Frailty Risk Factors in Community-Dwelling Older Adults: The SUNFRAIL+ Study Protocol. Int J Environ Res Public Health. 2023 Feb 21;20(5):3861. doi: 10.3390/ijerph20053861.
PubMed 36900872Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001 Jul;2(4):297-307. doi: 10.1016/s1389-9457(00)00065-4.
PubMed 11438246Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009 Sep;34(3):648-54. doi: 10.1183/09031936.00102509.
PubMed 19720809Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol. 1989;42(8):703-9. doi: 10.1016/0895-4356(89)90065-6.
PubMed 2760661Vitacca M, Paneroni M, Baiardi P, De Carolis V, Zampogna E, Belli S, Carone M, Spanevello A, Balbi B, Bertolotti G. Development of a Barthel Index based on dyspnea for patients with respiratory diseases. Int J Chron Obstruct Pulmon Dis. 2016 Jun 7;11:1199-206. doi: 10.2147/COPD.S104376. eCollection 2016.
PubMed 27354778ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available.
PubMed 12091180Blaylock A, Cason CL. Discharge planning predicting patients' needs. J Gerontol Nurs. 1992 Jul;18(7):5-10. doi: 10.3928/0098-9134-19920701-05.
PubMed 1629535J. E. Cotes, D. J. Chinn, MRC questionnaire (MRCQ) on respiratory symptoms. Occupational Medicine 2007; 57 (5): 388. https://doi.org/10.1093/occmed/kqm051.
Vitacca M, Olivares A, Borri R, Torlaschi V, Gazzi L, Portolani DM, Lastoria C, Aggiato S, Candia C, Maniscalco M, Cassetti G, Vigore M, Merla S, Steinhilber G, Moretta P. Prevalence and impact of psychiatric and neurocognitive comorbidities on pulmonary rehabilitation outcomes. Eur J Intern Med. 2026 Jun 5:106982. doi: 10.1016/j.ejim.2026.106982. Online ahead of print.
PubMed 42248735
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Respiratory Rehabilitation and the Impact of Psychiatric Comorbidities
- ClinicalTrials.gov ID
- NCT06229600
- Acronym / sponsor ID
- REHABPSY / CET 2023-3.11/439.1
- Conditions
- Respiratory Disease
- Keywords
- Chronic respiratory insufficiency, Cognitive impairment, Mental Health, COPD, Lung diseases
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 994 participants (actual)
- Lead sponsor
- Istituti Clinici Scientifici Maugeri SpAUniversity, hospital or other
- Study start
- 2 Jan 2024 (actual)
- Primary completion
- 31 Mar 2025 (actual)
- Study completion
- 31 Jul 2025 (actual)
- First posted
- 29 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with respiratory insufficiency, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, asthma, bronchiectasis, and, to a lesser extent, other pathologies that result in respiratory insufficiency and require rehabilitation are admitted to in-hospital Respiratory Rehabilitation. Several studies have assessed the impact of comorbidities in the most frequent respiratory diseases such as COPD, asthma, pulmonary fibrosis, and cystic fibrosis in terms of worsening mortality, morbidity, and disease progression.
However, to our knowledge, there is no reliable quantification in Italy of the percentage of the presence of mental disorders (psychiatric/neurodegenerative) according to the Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-5 classification in respiratory patients as well as the prevalence of mental disorders present among patients requiring in-hospital rehabilitation programs.
The study hypothesizes that these disorders are present among patients admitted to rehabilitation centers and that they may impact the final rehabilitation outcome.
Detailed description
Patients with respiratory insufficiency, COPD, pulmonary fibrosis, asthma, bronchiectasis, and, to a lesser extent, other pathologies that result in respiratory insufficiency and require rehabilitation are admitted to in-hospital Respiratory Rehabilitation. Several studies have assessed the impact of comorbidities in the most frequent respiratory diseases such as COPD, asthma, pulmonary fibrosis, and cystic fibrosis in terms of worsening mortality, morbidity, and disease progression.
Comorbidities have been studied and assessed by scales such as the COTE, the Charlson comorbidity index (CCI), and the Cumulative Illness Rating Scale (CIRS). These comorbidities assessed predominantly focus on metabolic and cardiovascular aspects and only a small number of studies considered psychiatric comorbidity, mainly depression.
In previous studies depression, anxiety and psychiatric disease were 8th, 14th, and 23rd in frequency as comorbidity.
Other, more evaluated comorbidities were high blood pressure (17%-64.7%), coronary artery disease (19.9%-47.8%), diabetes mellitus (10.2%-45%) osteoarthritis (18%-43.8%), psychiatric conditions (12.1%-33%) and asthma (14.7%-32.5%).
Among psychological/psychiatric/neurodegenerative comorbidities, anxiety, and depression have been more extensively studied, with worse rehabilitation outcomes, more symptoms (especially dyspnoea), less functional exercise capacity, and minor quality of life (QOL). Similarly, patients with COPD and obstructive sleep apnea syndrome (OSAS), as demonstrated in numerous studies, are more frequently affected by neurocognitive disorders.
Gender differences in reporting psychiatric and respiratory comorbidity have been previously observed: twice as many psychiatric disorders in women as in men, and with higher levels of anxiety and depression in women than in men.
Pulmonary diseases are historically and etiologically related to smoking and unfavorable environmental exposures, two factors that are more present in less affluent social groups, where an increase in psychiatric diseases is known. People with psychiatric diseases and fewer contextual resources also arrive later to be diagnosed with COPD and/or lung cancer, thus leading to a more unfavorable course.
Respiratory rehabilitation is for some respiratory diseases the standard of care among non-pharmacological therapies and should possibly lead to a return to a state of health identified as the person's 'well-being'. As recently published in a study conducted by the Italian Health Ministry, only 18% of Italians feel in a state of full well-being, understood as a state of complete physical, mental, and social well-being and not simply the absence of disease', indicating how complex it is to achieve this state, particularly for people with respiratory pathologies.
In recent years, therefore, there has been growing scientific evidence that there is a close correlation between mental and physical health to achieve maximum well-being also understood as 'the ability to adapt and self-manage in the face of social, physical and emotional challenges. For some years now, and even more after the recent severe acute respiratory syndrome (SARS)-CoV-2 pandemic outbreak, more and more attention has been paid to psychological and psychiatric disorders, especially anxiety, depression, and substance abuse.
Patients admitted to in-hospital respiratory rehabilitation often have complex comorbidities that affect recovery after an acute event.
These studies suggest that psychiatric/neurodegenerative pathologies may therefore significantly impact the patient's condition by increasing the risk of developing pulmonary disease, slowing down diagnosis and treatment, and acting as a brake on the possibility of deriving maximum benefit from pharmacological and non-pharmacological treatments such as rehabilitation and the continuation of adequate chronic disease management at home.
To our knowledge, there is no reliable quantification in Italy of the percentage of the presence of mental disorders (psychiatric/neurodegenerative) according to the DSM-5 classification in respiratory patients as well as the prevalence of mental disorders present among patients requiring in-hospital rehabilitation treatment.
The study hypothesizes that these disorders are present among patients admitted to rehabilitation centers and that they may impact the final rehabilitation outcome for various reasons, including a reduced awareness of one's health condition, greater difficulty in therapeutic adherence, the ability to self-monitor, the reduction of risk factors and a reduced availability of resources. This also results in reduced effectiveness of the education provided.
The presence of mental disorders also has a significant impact on family members and caregivers who should ultimately participate in the full implementation of the rehabilitation project. We consider as important to evaluate this aspect as well with this Italian-based survey.
With this study we therefore intend to assess in our Institutes how many people arrive with a diagnosis and/or treatment for mental disorders, how many need attention, and how many are identified or suspected to be affected by a psychiatric/neurodegenerative disease during their stay, during routine assessments, collecting clinical history, treatment and comorbidities. Treating the patient as a clinical team with multiple approaches, it can be argued that clinically significant signs and symptoms of psychiatric/neurocognitive disorders are detected with adequate accuracy even in the absence of formal psychiatric assessment, which would make the study unduly burdensome in the setting of interest and could undermine patient acceptance.
All adult patients consecutively admitted for a course of Respiratory Rehabilitation - in 12 months - to the Units of Respiratory Rehabilitation belonging to the Department of Pneumology of the Maugeri Scientific Clinical Institutes will be studied. On admission (T0), anthropometric, clinical history (comorbidities measured with CIRS scale, presence of chronic respiratory failure (CRF), oxygen (O2) use, smoking history with number of packs/year, drug therapy, number of respiratory flare-ups per year, number of respiratory hospitalizations per year, days since respiratory index event, admission diagnosis, and current medication history will be collected.
Moreover:
- Frailty assessment: Sunfrail tool (ST) is a questionnaire for measuring frailty among older people. ST is a 9-item questionnaire consisting of nine questions selected from evidence-based tools already used in health services in the European Union and the USA to identify frailty in the bio (physical), psycho (cognitive and psychological), and social domains. The answer can be yes or no. Important is the percentage of yes, and important is frailty.
- Pulmonary function assessment of forced expiratory volume at one second (FEV1), forced vital capacity (FVC), and FEV1/FVC; if the patient is respiratory insufficient: saturation of oxygen (SatO2) in oxygen/air, oxygen desaturation index (ODI)/h, average night SatO2, and time under 90% oxygen saturation (T<90).
- Psychological/neuropsychological assessment by the Centre's psychologists only if specifically requested during the rehabilitation program by the relevant clinician.
- Sleep survey: Insomnia Severity Index. Designed as a brief screening tool for insomnia, the seven-item questionnaire Insomnia Severity Index (ISI) asks respondents to rate the nature and symptoms of their sleep problems using a Likert-type to rate each item (e.g., 0 = no problem; 4 = very severe problem), yielding a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).
At the time of discharge from rehabilitation, patients will be classified according to the group A-F definition.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Group A | – | Other: Standard rehabilitationPatients with an established diagnosis according to the DSM-5 classification (DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS - FIFTH EDITION, 2014) and possible drug therapy (24). * Schizophrenia spectrum disorders and other psychotic disorders * Bipolar disorder and related disorders * Depressive disorders * Anxiety disorders * Obsessive-compulsive disorder and related disorders * Disorders related to traumatic and stressful events * Dissociative disorders * Somatic symptoms and related disorders * Nutrition and eating disorders * Evacuation disorders * Sleep-wake disorders * Sexual dysfunctions * Gender dysphoria * Disruptive behaviour, impulse control and conduct disorder * Substance-related and addiction disorders * Personality disorders * Paraphilia disorders * Autism spectrum disorders * ADHD |
| Group B | – | Other: Standard rehabilitationPatients on medication (psychotropic drugs) without a reported/reported specific psychiatric diagnosis in their clinical history. |
| Group C | – | Other: Standard rehabilitationPatients without a history/reported psychiatric disorder and without specific psychopharmacological therapy. |
| Group D | – | Other: Standard rehabilitationPatients with a history of diagnosed neurocognitive disorder. |
| Group E | – | Other: Standard rehabilitationPatients in the practice without a history/report of psychiatric disorders and without specific psychopharmacological treatment on admission who are diagnosed during admission. This is a subgroup of the C group. |
| Group F | – | Other: Standard rehabilitationPatients in the practice without a history/report of psychiatric disorders and without specific psychopharmacological therapy on admission who are diagnosed during admission for suspected psychiatric/neurocognitive pathology and are discharged with indications for further investigation at the territorial services. This is a subgroup of the C group. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- On admission (T0), clinical history, admission diagnosis, and current medication history will be collected for all patients admitted for respiratory rehabilitation. All patients will follow their tailored rehabilitation program according to the medical indication. At the time of discharge, they will be classified into six groups (A-F) according to the presence/absence of a psychiatric/cognitive diagnosis and/or pharmacological therapy.
Key inclusion criteria (1 listed)
- Older than 18 years of age, of either sex, eligible for admission to a Respiratory Rehabilitation Unit and who have signed the informed consent attesting to the patient's voluntary participation.
Key exclusion criteria (1 listed)
- Patients unable to read, with significant speech and hearing impairment,or refusing participation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard rehabilitationRespiratory rehabilitation | Other | Group A, Group B, Group C, Group D, Group E, Group F |
Primary outcome
Frequency of patients with or without comorbidities of psychiatric/neurocognitive disorders present on discharge from a respiratory rehabilitation program
Time frame: At one month
To quantify the percentage of patients in the study with or without comorbidities of psychiatric/neurocognitive disorders present on discharge from a respiratory rehabilitation pathway as follows: 1. established psychiatric diagnosis and drug therapy 2. drug therapy (psychotropic drugs) without a specific psychiatric diagnosis reported/reported in the history 3. no history/reported psychiatric disorder and no specific psychopharmacological therapy 4. history of diagnosis of neurocognitive disorder 5. absence of history/report of psychiatric disorders and without specific psychopharmacological treatment in inpatients receiving a diagnosis during admission 6. absence of history/report of psychiatric disorders and without specific psychopharmacological therapy on admission who receive a diagnosis during admission for suspected psychiatric/neurocognitive pathology and are discharged with indications for further investigation at the territorial services
8 secondary outcomes
Gender difference
Time frame: At one month
Response to rehabilitation on disease impact: CAT
Time frame: At baseline and one month
Response to rehabilitation on motor disability: Barthel Index
Time frame: At baseline and one month
Response to rehabilitation on frailty: BRASS
Time frame: At baseline and one month
Response to rehabilitation on dyspnea symptoms: Medical Research Council (MRC)
Time frame: At baseline and one month
Response to rehabilitation on dyspnea symptoms: Barthel Dyspnoea Index (Bld)
Time frame: At baseline and one month
Response to rehabilitation on effort tolerance: 6-Minute Walking Test (6MWT)
Time frame: At baseline and one month
Prevalence of the anamnestic factors in all groups
Time frame: At baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Background: PubMed 36900872De Luca V, Femminella GD, Leonardini L, Patumi L, Palummeri E, Roba I, Aronni W, Toccoli S, Sforzin S, Denisi F, Basso AM, Ruatta M, Obbia P, Rizzo A, Borgioli M, Eccher C, Farina R, Conforti D, Mercurio L, Salvatore E, Gentile M, Bocchino M, Sanduzzi Zamparelli A, Viceconte G, Gentile I, Ruosi C, Ferrara N, Fabbrocini G, Colao A, Triassi M, Iaccarino G, Liotta G, Illario M. Digital Health Service for Identification of Frailty Risk Factors in Community-Dwelling Older Adults: The SUNFRAIL+ Study Protocol. Int J Environ Res Public Health. 2023 Feb 21;20(5):3861. doi: 10.3390/ijerph20053861.
- Background: PubMed 11438246Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001 Jul;2(4):297-307. doi: 10.1016/s1389-9457(00)00065-4.
- Background: PubMed 19720809Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009 Sep;34(3):648-54. doi: 10.1183/09031936.00102509.
- Background: PubMed 2760661Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol. 1989;42(8):703-9. doi: 10.1016/0895-4356(89)90065-6.
- Background: PubMed 27354778Vitacca M, Paneroni M, Baiardi P, De Carolis V, Zampogna E, Belli S, Carone M, Spanevello A, Balbi B, Bertolotti G. Development of a Barthel Index based on dyspnea for patients with respiratory diseases. Int J Chron Obstruct Pulmon Dis. 2016 Jun 7;11:1199-206. doi: 10.2147/COPD.S104376. eCollection 2016.
- Background: PubMed 12091180ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available.
- Background: PubMed 1629535Blaylock A, Cason CL. Discharge planning predicting patients' needs. J Gerontol Nurs. 1992 Jul;18(7):5-10. doi: 10.3928/0098-9134-19920701-05.
- BackgroundJ. E. Cotes, D. J. Chinn, MRC questionnaire (MRCQ) on respiratory symptoms. Occupational Medicine 2007; 57 (5): 388. https://doi.org/10.1093/occmed/kqm051.
- Results publication: PubMed 42248735Vitacca M, Olivares A, Borri R, Torlaschi V, Gazzi L, Portolani DM, Lastoria C, Aggiato S, Candia C, Maniscalco M, Cassetti G, Vigore M, Merla S, Steinhilber G, Moretta P. Prevalence and impact of psychiatric and neurocognitive comorbidities on pulmonary rehabilitation outcomes. Eur J Intern Med. 2026 Jun 5:106982. doi: 10.1016/j.ejim.2026.106982. Online ahead of print.
- Individual participant dataSharing planned: No. All collaborating centers will manage pseudo-anonymized data by a proper eCRF to the coordinating center (ICSM Lumezzane) at the end of each month for 12 months. Data will be collected in a unique database managed by a health professional external to the research.
Related trials for Respiratory Disease
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michele Vitacca, MD principal investigator
Istituti Clinici Scientifici Maugeri
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Respiratory Disease, run by Istituti Clinici Scientifici Maugeri SpA at 6 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Frequency of patients with or without comorbidities of psychiatric/neurocognitive disorders present on discharge from a respiratory rehabilitation program (time frame: At one month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06229600, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.